Clinical Trial Update: Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty

View source ↗

Summary

A clinical trial evaluating rivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee arthroplasty has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Venous Thromboembolism | Status: COMPLETED